About
CPhI South East AsiaCPhI South East Asia
Industry Trade Show
Not Confirmed
16-18 July, 2025
Industry Trade Show
Attending
04-06 September, 2025
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Booth #9.1A6
28-30 October, 2025
CONTACT DETAILS
Digital content 
NEWS #PharmaBuzz
11 Jun 2025
// FDA
03 Feb 2025
// FDA
21 Aug 2024
// FDA
05 Aug 2024
// FDA
15 May 2023
// HEALTH ET
02 May 2023
// FDA
Drugs in Development
Lead Product(s) : Cannabidiol
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biophore, Its Subsidiary Zenara Pharma, Receive First Approval for Cannabidiol in India
Details : Cannabinoid oral solution has received approval for the treatment of several neurological disorders. It functions by stimulating two receptors, cannabinoid receptor type 1 and type 2, within the endocannabinoid system, maintaining body's homeostatis.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 15, 2023
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Zenara Pharma to Launch Generic Paxlovid Soon
Details : Zenara said Nirmatrelvir and Ritonavir tablets will soon be available in a combi-pack, sold under the brand name Paxzen, as a treatment of mild-to-moderate Covid-19 in adults.
Product Name : Paxzen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 28, 2022
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zenara Pharma, a Biophore Subsidiary, Gets DCGI Nod for Favipiravir Tablets
Details : Favipiravir tablets will be sold under the brand name ‘Favizen’, is being manufactured at Zenara’s US FDA approved facility in Hyderabad.
Product Name : Favizen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zenara Pharma Receives DCGI Approval to Manufacture, Sell Favipiravir Tablets
Details : Zenara Pharma has received approval from the Drugs Controller General of India (DCGI), to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of COVID-19.
Product Name : Favizen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
Dosage Form : TABLET; ORAL
Proprietary Name : BREXPIPRAZOLE
Dosage Strength : 0.25MG
Approval Date :
Application Number : 213477
RX/OTC/DISCN :
RLD :
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : BREXPIPRAZOLE
Dosage Strength : 0.5MG
Approval Date :
Application Number : 213477
RX/OTC/DISCN :
RLD :
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : BREXPIPRAZOLE
Dosage Strength : 1MG
Approval Date :
Application Number : 213477
RX/OTC/DISCN :
RLD :
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : BREXPIPRAZOLE
Dosage Strength : 2MG
Approval Date :
Application Number : 213477
RX/OTC/DISCN :
RLD :
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : BREXPIPRAZOLE
Dosage Strength : 3MG
Approval Date :
Application Number : 213477
RX/OTC/DISCN :
RLD :
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : BREXPIPRAZOLE
Dosage Strength : 4MG
Approval Date :
Application Number : 213477
RX/OTC/DISCN :
RLD :
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : PRUCALOPRIDE SUCCINATE
Dosage Strength : EQ 1MG BASE
Approval Date :
Application Number : 218795
RX/OTC/DISCN :
RLD :
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : PRUCALOPRIDE SUCCINATE
Dosage Strength : EQ 2MG BASE
Approval Date :
Application Number : 218795
RX/OTC/DISCN :
RLD :
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : SAFINAMIDE MESYLATE
Dosage Strength : EQ 50MG BASE
Approval Date :
Application Number : 215913
RX/OTC/DISCN :
RLD :
TE Code :
Dosage Form : TABLET; ORAL
Proprietary Name : SAFINAMIDE MESYLATE
Dosage Strength : EQ 100MG BASE
Approval Date :
Application Number : 215913
RX/OTC/DISCN :
RLD :
TE Code :
GDUFA
API Manufacturer :
FDF Manufacturer : FDF MANUFACTURE
Facility Name : ZENARA PHARMA PRIVATE LIMITED
Business Address : Plot No. 83/B, 84, 87 to 96,...
FEI Number : 3005485158
Country : India
Paid in : 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Zenara Pharma
Share 
